Cerus Corporation (NASDAQ:CERS) : Traders are bullish on Cerus Corporation (NASDAQ:CERS) as it has outperformed the S&P 500 by a wide margin of 4.23% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.57%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.87% in the last 1 week, and is up 5.91% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 21.70% from its 1 Year high price. On Apr 22, 2016, the shares registered one year high at $6.89 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $5.92 and the 200 Day Moving Average price is recorded at $5.80.
The stock has recorded a 20-day Moving Average of 5.87% and the 50-Day Moving Average is 10.56%.
Cerus Corporation (NASDAQ:CERS): stock turned positive on Friday. Though the stock opened at $6.39, the bulls momentum made the stock top out at $6.52 level for the day. The stock recorded a low of $6.39 and closed the trading day at $6.45, in the green by 1.42%. The total traded volume for the day was 1,812,204. The stock had closed at $6.36 in the previous days trading.
In an insider trading activity,The officer (Chief Legal Officer) of Cerus Corp, Menard Chrystal sold 8,541 shares at $5.62 on March 11, 2016. The Insider selling transaction had a total value worth of $48,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Companys INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.